Negreiros Elizete, Bueno da Silveira Talita Máira, Fortier Sérgio Costa, Chiattone Carlos Sérgio
Irmandade da Santa Casa de Misericórdia de São Paulo, Faculdade de Ciências Médicas da Santa Casa de São Paulo. São Paulo SP, Brazil.
Irmandade da Santa Casa de Misericórdia de São Paulo, Faculdade de Ciências Médicas da Santa Casa de São Paulo. São Paulo SP, Brazil.
Hematol Transfus Cell Ther. 2024 Dec;46 Suppl 6(Suppl 6):S53-S58. doi: 10.1016/j.htct.2023.11.005. Epub 2023 Dec 26.
To assess the prognostic value of C-Reactive Protein (CRP), at diagnosis and during follow-up, of patients with Hodgkin´s Lymphoma treated at the Hematology Service of the Santa Casa de São Paulo Hospital, and to correlate serum CRP levels with disease stage and treatment response.
A retrospective study involving review of 71 medical records of patients diagnosed with Hodgkin´s Lymphoma between February 2012 and January 2016 was performed. Three patients were subsequently excluded, giving a total of 68 patients for analysis. A level of CRP > 1 mg/dl was considered elevated.
Patients were predominantly male (61.8 %) and mean age was 34 years. Fifty-three (78 %) patients had advanced stage and (76.5 %) had B symptoms. Elevated baseline CRP was associated with greater likelihood of B symptoms (p = 0.02) and of advanced stage (p = 0.015). Patients with Low CRP level after 5th and 6th cycles of chemotherapy was associated with complete response (p = 0.04 and p = 0.03, respectively). Treatment-refractory patients had greater risk of death (p = 0.002).
CRP is clinically important for follow-up of patients with Hodgkin´s Lymphoma, where high levels were associated with advanced disease and/or presence of B symptoms. CRP level was considered a predictor of treatment response. Persistence of high CRP values during treatment was associated with refractoriness.
评估圣保罗圣卡塔琳娜医院血液科治疗的霍奇金淋巴瘤患者诊断时及随访期间C反应蛋白（CRP）的预后价值，并将血清CRP水平与疾病分期和治疗反应相关联。
进行一项回顾性研究，回顾了2012年2月至2016年1月期间诊断为霍奇金淋巴瘤的71例患者的病历。随后排除了3例患者，共68例患者进行分析。CRP水平>1mg/dl被认为升高。
患者以男性为主（61.8%），平均年龄34岁。53例（78%）患者处于晚期，76.5%有B症状。基线CRP升高与出现B症状（p=0.02）和晚期（p=0.015）的可能性更大相关。化疗第5和第6周期后CRP水平低的患者与完全缓解相关（分别为p=0.04和p=0.03）。治疗难治性患者死亡风险更高（p=0.002）。
CRP对霍奇金淋巴瘤患者的随访具有重要临床意义，高水平与疾病晚期和/或B症状的存在相关。CRP水平被认为是治疗反应的预测指标。治疗期间CRP值持续升高与难治性相关。
